Pharmacist Strategies for Mitigating Patient Harm, Inequities During Drug Shortages
Drug Topics
APRIL 8, 2024
Researchers addressed pharmacists’ role in mitigating drug shortages.
Mon.Apr 08, 2024
201 
Opinion: The time has come for over-the-counter antidepressants
STAT
APRIL 8, 2024
Anyone can now walk into a pharmacy in the United States and buy oral contraceptives over the counter without a prescription, thanks to the FDA’s approval of norgestrel (Opill). This change reflects the drug’s safety and the public health imperative to ensure wider access to birth control. But another safe class of medicine that addresses a massive public health need remains unavailable except by prescription: the antidepressants known as selective serotonin reuptake inhibitor
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Methotrexate, Leflunomide Linked to Higher Risk of Adverse Pregnancy Outcomes in Patients With RA
Drug Topics
APRIL 8, 2024
Due to the increased possibility of adverse pregnancy outcomes associated with methotrexate and leflunomid, it is crucial that patients with rheumatoid arthritis (RA) engage in thorough consultations with their physicians regarding pregnancy planning.
STAT+: New liquid biopsy screening test for pancreatic cancer shows promise in early data
STAT
APRIL 8, 2024
For the vast majority of pancreatic cancer cases, the tumor grows undetected until it has already spread locally or to distant parts of the body. That means most patients, over 80% by some estimates, are diagnosed when it’s already too late to do surgery — depriving them of their best chance for a cure. “For the majority of patients, we cannot resect the tumor.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Mental health tech startup Grow Therapy snags $88M, builds out measurement-based care tech
Fierce Healthcare
APRIL 8, 2024
Grow Therapy, a mental health technology startup, picked up $88 million in fresh funding to grow its footprint and launch more partnerships with payers. | Grow Therapy, a mental health technology startup, picked up $88 million in fresh funding to grow its footprint and launch more partnerships with payers.
STAT+: HCA reports almost $1 billion more in charity care to Medicare than to its shareholders, drawing more taxpayer money
STAT
APRIL 8, 2024
The country’s biggest hospital chain, HCA Healthcare , told the Centers for Medicare and Medicaid Services it doled out almost $1 billion more in financial assistance to needy patients than it reported on its financial statement in 2022, helping the enormously profitable company extract billions of dollars from taxpayer-funded programs. It’s normal for hospital systems to report more charity care — free and discounted care provided to low-income patients — in their an
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
Patient with transplanted pig kidney had a ‘tense’ rejection episode before leaving the hospital
STAT
APRIL 8, 2024
The world’s first recipient of a kidney transplant from a genetically modified pig experienced a rejection episode before recovering and leaving the hospital last week, a Massachusetts General Hospital doctor told STAT. But in his first few days back at home in Weymouth, Mass., the patient — 62-year-old Richard Slayman — had shown no further signs of organ distress.
With wider approval, J&J and Legend's Carvykti quickly leaps ahead of BMS' rival myeloma CAR-T
Fierce Pharma
APRIL 8, 2024
Merely hours after Bristol Myers Squibb’s Abecma secured the FDA’s blessing to break into earlier treatment of multiple myeloma, Johnson & Johnson and Legend Biotech’s Carvykti received a simil | Merely hours after Bristol Myers Squibb’s Abecma secured the FDA’s blessing to break into earlier treatment of multiple myeloma, Johnson & Johnson and Legend Biotech’s Carvykti received a similar go-ahead—but in an even earlier setting and with expanded manufacturing specifications.
Medicaid redetermination cost community health centers an average of $600K each
STAT
APRIL 8, 2024
It’s been a year since states began the process of Medicaid redetermination, going through their Medicaid rolls that had been frozen through the Covid-19 emergency period. According to data from KFF , about 21% of the people who were enrolled prior to the redetermination, or close to 20 million, lost coverage, while 45%, or 42 million, were confirmed.
AstraZeneca, Daiichi Sankyo's Enhertu wins historic HER2 tumor-agnostic FDA nod
Fierce Pharma
APRIL 8, 2024
With Enhertu at the heart of AstraZeneca and Daiichi Sankyo’s respective goals for oncology growth, the partners have significantly expanded the antibody-drug conjugate’s (ADC's) reach in the U.S.< | With Enhertu at the heart of AstraZeneca and Daiichi Sankyo’s respective goals for oncology growth, the partners have significantly expanded the antibody-drug conjugate’s reach in the United States.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Next-gen menopause treatments have blockbuster potential. Can women, doctors and payers be convinced?
PharmaVoice
APRIL 8, 2024
The market is huge, but will companies overcome the triple hurdles of payer hesitance, prescriber reluctance and sluggish consumer demand?
'Most' cancer meds approved under FDA's accelerated pathway couldn't prove survival benefit after 5 years: study
Fierce Pharma
APRIL 8, 2024
One hallmark of the FDA's accelerated approval pathway is the requirement that medicines prove their benefits in confirmatory trials. | Many cancer meds approved under the FDA's accelerated approval pathway from 2013 to 2017 didn't improve overall survival after more than five years of follow-up research, the study found.
Women’s health and digital tech empowerment
pharmaphorum
APRIL 8, 2024
Empower women's health with digital tools and technology. Learn about the latest advancements and resources to promote wellness and empowerment in women's health.
FDA swats away Supernus’ Parkinson’s disease infusion pump for 3rd time
Fierce Pharma
APRIL 8, 2024
The third time is decidedly not the charm for Supernus and its Parkinson’s disease infusion pump. | The FDA refused to accept Supernus' first approval bid after the company acquired the med in 2020. The following year, the agency doled out a complete response letter, dashing Supernus' second try.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Jardiance doesn’t cut it in post-heart attack trial
pharmaphorum
APRIL 8, 2024
SGLT2 inhibitors have transformed the treatment of heart failure in the last few years, but an attempt to extend their use into the setting of post-heart attack patients has suffered a setback.
FDA Approves Dolutegravir/Lamivudine for Treatment of Adolescents With HIV-1 Infection
Pharmacy Times
APRIL 8, 2024
The treatment is indicated for adolescents at least 12 years of age who weigh at least 25 kg without a previous treatment history of antiretroviral therapies.
Fitch: MA utilization spike clouds outlook for payers in early 2024
Fierce Healthcare
APRIL 8, 2024
Health insurers are gearing up to release their first-quarter results over the next several weeks, and a new analysis from Fitch Ratings finds that ongoing concern about utilization in Medicare Adv | A new analysis from Fitch Ratings finds that ongoing concern about utilization in Medicare Advantage has made for a cloudy outlook.
Changing Faces: Pharma and biotech hires from March 2024
pharmaphorum
APRIL 8, 2024
Stay up to date with the latest pharma and biotech hires from March 2024, including notable companies like Sitryx, Oxford, and MaaT Pharma.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
STAT+: Device made by company J&J is buying for $13 billion clears hurdle in independent study
STAT
APRIL 8, 2024
A fully independent clinical trial researchers thought might disprove a cardiac device made by Shockwave Medical, the company that Johnson & Johnson is buying for $13 billion, ended up providing some support for the device’s utility. The data, presented Monday at the annual meeting of the American College of Cardiology and published in The Lancet , could bolster the case for the device, which is available in Europe and the U.K. but was previously rejected by the U.S.
Creating a winning playbook for consistent digital product success
pharmaphorum
APRIL 8, 2024
Creating a winning playbook for consistent digital product success involves strategic planning, execution, and continuous improvement. Discover key strategies and practices to ensure your digital products achieve lasting success.
More Research Needed for Treatment of Clozapine-Resistant Schizophrenia
Pharmacy Times
APRIL 8, 2024
Current evidence and data regarding clozapine-resistant schizophrenia is unclear, but new treatment options are on the horizon that could show promise.
Ionis, Arrowhead hail data with triglyceride drugs at ACC
pharmaphorum
APRIL 8, 2024
Drugs from Ionis and Arrowhead Pharma that block apolipoprotein C-III (apoC-III) have shown their value in treating diseases associated with elevated triglyceride levels in two studies presented at the American College of Cardiology annual congress. The two companies are racing to bring their apoC-III inhibitors to market for severe hypertriglyceridaemia (HTG) and ultra-rare disorder familial chylomicronaemia syndrome (FCS).
Novel Approaches to Treating the Full Spectrum of Schizophrenia Symptoms, Modulating Dopamine and Glutamate Neurotransmission
Pharmacy Times
APRIL 8, 2024
New approaches for treating all schizophrenia symptoms by modulating dopamine and glutamate in non-traditional ways.
Enhertu gets FDA nod for tumour-agnostic HER2 cancers
pharmaphorum
APRIL 8, 2024
FDA approves AstraZeneca and Daiichi Sankyo’s Enhertu for all HER2-positive solid tumours, in a first for both the HER2 inhibitor and ADC category.
HCA’s charity care filings are on hyperdrive
STAT
APRIL 8, 2024
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money in medicine. Sign up to get it in your inbox every Monday. The funny business of reporting charity care The concept of charity care is simple: It’s the free and discounted care that hospitals provide to low-income people.
Study points to weaknesses in FDA accelerated approval path
pharmaphorum
APRIL 8, 2024
Less than half of the cancer therapies given accelerated approval by the FDA in 2013 to 2017 showed a clinical benefit in a confirmatory trial within the next five years
Safety Data Confirm Viability of Flu, RSV Vaccines For Patients at Risk of Heart Failure
Pharmacy Times
APRIL 8, 2024
Investigators reported a low incidence of adverse events after simultaneous vaccination against seasonal influenza and respiratory syncytial virus.
Unlocking growth: How GenAI can help pharma companies convert new clients
PharmaVoice
APRIL 8, 2024
GenAI is profoundly reshaping various facets of the pharmaceutical industry. Projections indicate that the global GenAI market in pharma will soar to USD 2258.1 million by 2032.
Empagliflozin Shows 10% Relative Risk Reduction in Time to First Hospitalization Due to Heart Failure
Pharmacy Times
APRIL 8, 2024
The finding did not reach statistical significance in the primary composite endpoint.
Ed Schoonveld Discusses Drug Pricing in the US and Upcoming Articles
Pharmaceutical Commerce
APRIL 8, 2024
In an interview with Pharma Commerce Editor Nicholas Saraceno, Ed Schoonveld, Value & Access Advisor, Schoonveld Advisory, offers his thoughts on lower drug prices in the US and provides a sneak peak into future PC features.
Women want to participate in clinical trials. Lack of flexibility is still a problem.
PharmaVoice
APRIL 8, 2024
Underrepresentation of women in clinical trials affects the resulting drugs that are available down the line. Encouraging more women to partake is a critical step in promoting more equitable healthcare.
FDA accepts Shorla’s oral liquid leukaemia drug NDA
Pharmaceutical Technology
APRIL 8, 2024
The FDA has approved the NDA for SH-201, an oral liquid drug that slows or stops the growth of certain types of leukaemia.
'Sobering' study finds nearly no benefits from medical debt relief efforts
Fierce Healthcare
APRIL 8, 2024
A nonprofit organization’s work buying out and forgiving billions of dollars of medical debt may not be helping patients as much as it or its benefactors had hoped, economists say. | An experimental review of medical debts relieved by the charity RIP Medical Debt in 2018 to 2020 showed near-negligible changes in credit, no improvement in financial well-being, no changes in repayment or utilization behaviors and worsened mental health among those with the most debts.
Let's personalize your content